There are several versions of Anamorelin and an introduction to their differences, advantages and disadvantages

Anamorelin () is an oral growth hormone secretion promoter, mainly used to treat cancer-related cachexia (cancer-induced wasting), especially in advanced patients such as lung cancer, showing the potential to improve appetite, weight and muscle mass. At present, the drug has not been approved for marketing in mainland China. If domestic patients need it, they must obtain it through cross-border drug purchase or overseas medical channels. In the international market, there are two main versions of Anamorelin: the original version produced by Japan's Ono Pharmaceutical (Ono Pharmaceutical), and the generic version launched by Laos' Luye Pharma (Luye Pharma/Luxus) and other companies. The two have differences in efficacy, safety and price.

The original version of Japan's Ono Pharmaceutical is the world's first approved anamorelin drug, with the trade name "Adlumiz". It is currently widely used in Japan to treat cachexia symptoms in patients with non-small cell lung cancer and other tumors. This version has the advantages of clinical data support, strict quality control, reliable stability and bioavailability. Feedback from users is generally positive, and it can significantly improve patients' appetite, weight and physical fitness, especially when combined with nutritional therapy. However, its price is relatively high. The monthly treatment cost is about more than 3,000 yuan, which belongs to the mid-to-high-end drug expenditure range and is not suitable for long-term use by patients with all economic conditions.

In comparison, the generic versions produced by manufacturers such as Laos Lucius are consistent with the original drug in terms of ingredients and dosage design, but there may be certain differences in production standards. The price of this version is obviously more affordable, with the cost of each course of treatment being about more than 2,000 yuan, and it is favored by many patients who want to save medical costs. However, because some generic drugs have not yet undergone a complete international quality certification process, the individual differences in efficacy are slightly larger. Clinicians generally recommend choosing carefully under the guidance of a doctor and paying attention to the reactions and effects during medication.

Overall, anamulin is still in the limited launch and gradual promotion stage around the world, mainly in countries such as Japan. The original version has advantages in safety and standardization and is suitable for patients who have higher requirements for efficacy or whose financial ability allows; the generic version provides an affordable option for more patients. In the future, as more countries around the world advance marketing approval, the version types and clinical coverage of anamulin may be further expanded, and the country is also expected to gradually introduce the drug with policy support and accumulation of clinical research to meet the urgent treatment needs of patients with cachexia.

Reference materials:https://www.drugs.com/